The Possible Direct Correlation between Cognitive Impairment and Fear of Catching COVID-19 among Patients with Multiple Sclerosis
Objective: The prevalence of cognitive impairment in multiple sclerosis (MS) is significant and it is estimated that 40% to 70% of patients with MS suffer from this impairment. COVID-19 is also a new infectious disease. The symptoms of this disease, which include fever, shortness of breath, and cough, can be mild to severe and can even lead to death. Due to the use of immunosuppressive drugs by Patients with MS, they might be at greater risk of catching COVID-19. Thus, patients with MS may be more afraid of catching the virus. One of the important factors is the relationship between cognitive deficit and the increase in patients' fear of COVID-19. The aim of this study was to assess the relationship between fear of catching COVID-19 and cognitive impairment in patients with MS.
Method: This cross-sectional study was conducted at the MS Clinic, Sina hospital, Tehran University of Medical Sciences, Tehran, Iran. Our participants in this project were Patients with MS who were over 18 years old and had no history of other neurological and psychiatric diseases. In addition to obtaining demographic and clinical information, we measured the fear of catching the COVID 2019 via Fear of COVID-19 Scale (FCV-19S), which is 7-item questionnaire. We also used Multiple Sclerosis Neuro Psychological Screening Questionnaire (MSNQ) to assess memory and information processing speed in Patients with MS.
Results: After adjustment for age, gender, disease duration, highest level of education, MS type, and EDSS in linear regression model, as well as the MSNQ total score and fear score of catching coronavirus, the results demonstrated a significant positive correlation with P value of 0.00 and β: 0.024.
Conclusion: The present study showed a direct relationship between cognitive disorder and level of fear regarding COVID-19. Patients with more cognitive disorders were more afraid of COVID-19.
2. McIntosh-Michaelis SA, Roberts MH, Wilkinson SM, Diamond ID, McLellan DL, Martin JP, et al. The prevalence of cognitive impairment in a community survey of multiple sclerosis. Br J Clin Psychol. 1991;30(4):333-48.
3. Grant I, McDonald WI, Trimble MR. Neuropsychological impairment in early multiple sclerosis. In: Jensen K, Knudsen L, Stenager E, Grant I (eds) Mental disorders and cognitive deficits in multiple sclerosis. London: Libbey; 1989:17–26.
4. Wishart H, Sharpe D. Neuropsychological aspects of multiple sclerosis: a quantitative review. J Clin Exp Neuropsychol. 1997;19(6):810-24.
5. Denney DR, Sworowski LA, Lynch SG. Cognitive impairment in three subtypes of multiple sclerosis. Arch Clin Neuropsychol. 2005;20(8):967-81.
6. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. Jama. 2020;323(11):1061-9.
7. Haines S, Caccamo A, Chan F, Galaso G, Catinchi A, Gupta PK. Practical considerations when performing neurodiagnostic studies on patients with COVID-19 and other highly virulent diseases. Neurodiagn J. 2020; 60(2):78-95.
8. Özdin S, Bayrak Özdin Ş. Levels and predictors of anxiety, depression and health anxiety during COVID-19 pandemic in Turkish society: The importance of gender. Int J Soc Psychiatry. 2020;66(5):504-11.
9. Xiang Y-T, Yang Y, Li W, Zhang L, Zhang Q, Cheung T, et al. Timely mental health care for the 2019 novel coronavirus outbreak is urgently needed. The Lancet Psychiatry. 2020;7(3):228-9.
10. Brooks SK, Webster RK, Smith LE, Woodland L, Wessely S, Greenberg N, et al. The psychological impact of quarantine and how to reduce it: rapid review of the evidence. Lancet. 2020;395(10227):912-20.
11. Ahorsu DK, Lin CY, Imani V, Saffari M, Griffiths MD, Pakpour AH. The Fear of COVID-19 Scale: Development and Initial Validation. Int J Ment Health Addict. 2020:1-9.
12. Owji M, Sahraian MA, Bidadian M, Ghadiri F, Etesam F, Azimi A, et al. Evaluating the relationship between emotional intelligence and cognitive disorders in patients with Multiple Sclerosis. Iran J Neurol. 2018;17(2):78-81.
13. Shahrbabak M. COMPARING NEURAL FATIGUE BETWEEN FOUR TYPES OF PATIENTS WITH MULTIPLE SCLEROSIS. Studies in Medical Sciences. 2012;23(2):164-71.
14. Mousavi S, Zare H, Etemadifar M, Taher Neshatdoost H. Memory rehabilitation for the working memory of patients with multiple sclerosis (MS). J Clin Exp Neuropsychol. 2018;40(4):405-10.
15. Benedict RH, Munschauer F, Linn R, Miller C, Murphy E, Foley F, et al. Screening for multiple sclerosis cognitive impairment using a self-administered 15-item questionnaire. Mult Scler. 2003;9(1):95-101.
16. Haines S, Caccamo A, Chan F, Galaso G, Catinchi A, Gupta PK. Practical considerations when performing neurodiagnostic studies on patients with COVID-19 and other highly virulent diseases. Neurodiagn J. 2020;60(2):78-95.
17. Rao SM, Leo GJ, Ellington L, Nauertz T, Bernardin L, Unverzagt F. Cognitive dysfunction in multiple sclerosis. II. Impact on employment and social functioning. Neurology. 1991;41(5):692-6.
18. DeLuca J, Chiaravalloti ND, Sandroff BM. Treatment and management of cognitive dysfunction in patients with multiple sclerosis. Nat Rev Neurol. 2020;16(6):319-32.
19. Moghadasi AN, Pourmand S, Sharifian M, Minagar A, Sahraian MA. Behavioral Neurology of Multiple Sclerosis and Autoimmune Encephalopathies. Neurol Clin. 2016;34(1):17-31.
20. Bond MR. Psychological issues in cancer and non-cancer conditions. Acta Anaesthesiol Scand. 2001;45(9):1095-9.
21. Rabinowitz AR, Arnett PA. Coping in neurological disorders. In Positive Neuropsychology. Springer, New York, NY; 2013:13-24.
22. Goretti B, Portaccio E, Zipoli V, Razzolini L, Amato MP. Coping strategies, cognitive impairment, psychological variables and their relationship with quality of life in multiple sclerosis. Neurol Sci. 2010;31(Suppl 2):S227-30.
23. Calandri E, Graziano F, Borghi M, Bonino S. Improving the quality of life and psychological well-being of recently diagnosed multiple sclerosis patients: preliminary evaluation of a group-based cognitive behavioral intervention. Disabil Rehabil. 2017;39(15):1474-81.
24. Serafini G, Parmigiani B, Amerio A, Aguglia A, Sher L, Amore M. The psychological impact of COVID-19 on the mental health in the general population. Qjm. 2020;113(8):531-7.
25. Alkhamees AA, Alrashed SA, Alzunaydi AA, Almohimeed AS, Aljohani MS. The psychological impact of COVID-19 pandemic on the general population of Saudi Arabia. Compr Psychiatry. 2020;102:152192.
26. Rodríguez-Rey R, Garrido-Hernansaiz H, Collado S. Psychological Impact and Associated Factors During the Initial Stage of the Coronavirus (COVID-19) Pandemic Among the General Population in Spain. Front Psychol. 2020;11:1540.
27. Luna G, Alping P, Burman J, Fink K, Fogdell-Hahn A, Gunnarsson M, et al. Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies. JAMA Neurol. 2020;77(2):184-91.
28. Giovannoni G, Hawkes C, Lechner-Scott J, Levy M, Waubant E, Gold J. The COVID-19 pandemic and the use of MS disease-modifying therapies. Mult Scler Relat Disord. 2020;39:102073.
29. Lester K, Stepleman L, Hughes M. The association of illness severity, self-reported cognitive impairment, and perceived illness management with depression and anxiety in a multiple sclerosis clinic population. J Behav Med. 2007;30(2):177-86.
30. Vissicchio NA, Altaras C, Parker A, Schneider S, Portnoy JG, Archetti R, et al. Relationship Between Anxiety and Cognition in Multiple Sclerosis: Implications for Treatment. Int J MS Care. 2019;21(4):151-6.
31. Marrie RA, Patel R, Figley CR, Kornelsen J, Bolton JM, Graff L, et al. Diabetes and anxiety adversely affect cognition in multiple sclerosis. Mult Scler Relat Disord. 2019;27:164-70.
32. Naser Moghadasi A. One Aspect of Coronavirus disease (COVID-19) Outbreak in Iran: High Anxiety among MS Patients. Mult Scler Relat Disord. 2020;41:102138.
33. Haji Akhoundi F, Sahraian MA, Naser Moghadasi A. Neuropsychiatric and cognitive effects of the COVID-19 outbreak on multiple sclerosis patients. Mult Scler Relat Disord. 2020;41:102164.
34. Motolese F, Rossi M, Albergo G, Stelitano D, Villanova M, Di Lazzaro V, et al. The Psychological Impact of COVID-19 Pandemic on People With Multiple Sclerosis. Front Neurol. 2020;11:580507.
35. Talaat F, Ramadan I, Aly S, Hamdy E. Are multiple sclerosis patients and their caregivers more anxious and more committed to following the basic preventive measures during the COVID-19 pandemic? Mult Scler Relat Disord. 2020;46:102580.
|Issue||Vol 16 No 3 (2021)|
|COVID-19 Cognitive Impairment Fear Multiple Sclerosis|
|Rights and permissions|
|This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.|